IT Administrator at MalamTeam @ Israel
Vant Chair at Roivant Sciences
Frank Torti is the Vant Chair at Roivant Sciences. In this role Dr. Torti serves as Chairman of the Board of the public and private biopharmaceutical companies (Vants) at Roivant and is responsible for those businesses. This group of companies has collectively advanced over forty medicines into clinical development, delivered positive phase three results in eight of nine consecutive clinical trials, and has created over five billion dollars in value. Dr. Torti previously served as Vant Investment Chair at Roivant where he was responsible for a family of companies at Roivant Pharma developing investigational drugs in eleven therapeutic areas and running over fifty clinical trials.
Prior to joining Roivant, Dr. Torti was a partner at New Enterprise Associates (NEA), one of the largest venture capital firms in the world. At NEA, Dr. Torti partnered with entrepreneurial companies at all stages of their lifecycle and oversaw both early and growth stage investments in companies that were responsible for the development and commercialization of several new drugs and medical devices important to clinical medicine today. The companies in which Dr. Torti invested include five "unicorn" companies that reached in excess of $1B in value and include: Annexon Biosciences (NASDAQ: ANNX), Cadence Pharmaceuticals (acquired by Mallinckrodt plc), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira (acquired by Eli Lilly), Eargo (NASDAQ: EAR), GST Clinics, Galera Therapeutics (NASDAQ: GRTX), Neotract (acquired by Teleflex), Novast Pharmaceuticals, OphoMed, Peplin (acquired by LEO Pharma), Solta Medical (acquired by Valeant), and Tarveda Therapeutics.
Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of clinical trials. Dr. Torti received his BA with highest honors as a Morehead Scholar at the University of North Carolina, his MD from the University of North Carolina School of Medicine, and his MBA with distinction from Harvard Business School.